<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126463</url>
  </required_header>
  <id_info>
    <org_study_id>LIP-RE-I</org_study_id>
    <nct_id>NCT01126463</nct_id>
  </id_info>
  <brief_title>188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas</brief_title>
  <acronym>LIP-RE-I</acronym>
  <official_title>Phase 1 Study of Hepatic Intra-Arterial Administration of 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the maximum tolerated dose and the recommended 188Re-SSS Lipiodol&#xD;
      activity for hepatic intra-arterial injection in patients with hepato-cellular carcinoma. The&#xD;
      new radioactive isotope 188Rhenium associated with Lipiodol is expected to reduce the&#xD;
      radioprotection constraints and hence the duration of the hospitalisation in a protected room&#xD;
      from 8 to 1 day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma is one of the most prevalent primary cancers in many countries. In&#xD;
      France, mortality due to HCC on viral C cirrhosis is going to increase of about 150% for men&#xD;
      and 200% for women until 2020. Consequently, HCC is a problem of public health.&#xD;
&#xD;
      The current treatment for HCC is mainly palliative with chemoembolization or intra-arterial&#xD;
      radiotherapy, and intra-arterial targeted radiotherapy being the best tolerated method&#xD;
      (iodine-131-labelled lipiodol being the most commonly used).&#xD;
&#xD;
      However, since 2007, a new therapeutic approach can be considered with oral sorafenib, an&#xD;
      anti-angiogenic drug which increases slightly the survival of patients.&#xD;
&#xD;
      The key for an efficient treatment of HCC is presumably a co-treatment of sorafenib and&#xD;
      intra-arterial radiotherapy. The 131I-lipiodol is a good candidate but presents&#xD;
      disadvantages: it requires hospitalization in a radionuclide therapy room for one week.&#xD;
      Therefore, it is necessary to find new radioactive labellings for lipiodol. In this&#xD;
      objective, 188Re-SSS lipiodol, a new radioactive labeled stable complex has been developed.&#xD;
      It has a short half-life and a tiny amount of gamma radiation compared to 131I-lipiodol, so&#xD;
      it allows to reduce hospitalization in a protected room from 8 days to only one day.&#xD;
&#xD;
      The aim of this study is to determine the Maximum Tolerated Dose and thus the recommended&#xD;
      activity of 188Re-SSS lipiodol by intra-arterial injection in patients with HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2010</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose</measure>
    <time_frame>Injection each week during 4 weeks and at month 2</time_frame>
    <description>Toxicity CTC grade ≥ 3 with CTCAE version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bio-availability</measure>
    <time_frame>1, 6, 24 et 48 hours after treatment injection</time_frame>
    <description>Measurement by gamma-scintigraphy and by measurement of radio-activity in urinary, faecal and blood samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatocellular Carcinomas</condition>
  <arm_group>
    <arm_group_label>Rhenium Lipiodol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic Intra-Arterial Administration of radio-active lipiodol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>188Re-SSS Lipiodol</intervention_name>
    <description>Hepatic Intra-Arterial Administration of radio-active lipiodol.</description>
    <arm_group_label>Rhenium Lipiodol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult over 18,&#xD;
&#xD;
          -  WHO performance status ≤ 2,&#xD;
&#xD;
          -  Hepatocellular carcinoma histologically or cytologically proven, or association of&#xD;
             liver tumor with chronic hepatopathy and AFP &gt; 400 ng/ml, or tumorous hepatic&#xD;
             formation considered as hypervascularised by at least 2 methods of imaging in&#xD;
             cirrhotic patient, Non operable, non resectable, non transplantable, non accessible to&#xD;
             percutaneous treatment tumor,&#xD;
&#xD;
          -  Measurable tumor, uni- or multinodular, taking up less than 50% of hepatic volume,&#xD;
&#xD;
          -  Stage A to C of the BCLC classification (or stage 0 to 4 of the CLIP) with:&#xD;
&#xD;
               -  No thrombosis of the portal vein, therapeutic escape or intolerance causing the&#xD;
                  end of the treatment or contraindication to sorafenib&#xD;
&#xD;
               -  If thrombosis of the portal vein, therapeutic escape to Lipiocis,&#xD;
&#xD;
          -  Possibility of treatment by intra-arterial radiotherapy over a decision of a&#xD;
             Multidisciplinary Committee,&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a stage ≥ 3 toxicity of the CTCAE version 4&#xD;
&#xD;
          -  Stage D of the classification BCLC&#xD;
&#xD;
          -  Acute impairment of hepatic functions (Child-Pugh B9 or C)&#xD;
&#xD;
          -  Grade III Hepatocarcinoma of the Okuda classification&#xD;
&#xD;
          -  Encephalopathy with troubles even moderated of cognitive functions&#xD;
&#xD;
          -  Advanced chronic respiratory insufficiency&#xD;
&#xD;
          -  Creatinine clearance &lt; 55 ml/min, polynuclear neutrophils &lt; 1500 G/L, platelets &lt; 50&#xD;
             G/L, prothrombin &lt; 40% (INR &gt; 2,3)&#xD;
&#xD;
          -  Contraindication to the intra-arterial administration&#xD;
&#xD;
          -  Patients who can't be followed up for psychological or geographic reasons&#xD;
&#xD;
          -  Patients dependant on another person for daily care&#xD;
&#xD;
          -  Urinary incontinence&#xD;
&#xD;
          -  Progressive cancer&#xD;
&#xD;
          -  Pregnant or breastfeeding woman, or not using adequate effective contraception method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne GARIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugene Marquis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Garin E, Rakotonirina H, Lejeune F, Denizot B, Roux J, Noiret N, Mesbah H, Herry JY, Bourguet P, Lejeune JJ. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma. Nucl Med Commun. 2006 Apr;27(4):363-9.</citation>
    <PMID>16531923</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinomas</keyword>
  <keyword>lipiodol</keyword>
  <keyword>rhenium</keyword>
  <keyword>Non operable Hepatocellular carcinomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

